Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Ajovy

- PMLiVE

Teva poaches Lundbeck’s Schultz as new CEO

Shares in Lundbeck fall as two senior posts become vacant

- PMLiVE

FDA clears Teva’s tardive dyskinesia drug Austedo

The twice-daily drug will compete with Neurocrine Bioscience’s Ingrezza

- PMLiVE

Teva to cut 7000 jobs, close 15 manufacturing sites

Missed second-quarter sales expectations prompt the cutbacks

- PMLiVE

Race to CGRP migraine drug finish line enters the final straight

US regulator keeps Aimovig ahead of competitors including Lilly’s galcanezumab

- PMLiVE

NICE backs Teva’s Cinqaero for severe asthma

Ruling will allow it to compete with GSK's rival IL-5 inhibitor Nucala

AstraZeneca AZ

AZ on the slide again as CEO departure rumours bubble away

Soriot’s alleged departure makes investors nervous ahead of looming MYSTIC trial results

AstraZeneca AZ

Grünenthal buys Zomig rights as AZ slimming drive continues

Acquires global rights outside Japan to the migraine drug

Eli Lilly HQ

Lilly set to head to regulators with CGRP migraine drug

Gathers three positive late-stage trials of galcanezumab as it chases Amgen

- PMLiVE

Teva drops laquinimod for most common form of MS after failed trial

CONCERTO study showed no disability progression improvements over placebo

- PMLiVE

Teva launches asthma social media campaign

Hopes awareness drive will improve inhaler use

- PMLiVE

FDA approves Teva’s Huntington’s disease drug at second attempt

Austedo will treat fatal degenerative disorder chorea

Teva launches online cancer portal My Day

Follows social listening project on gender differences in cancer discussions

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links